Ontology highlight
ABSTRACT:
SUBMITTER: Fedorenko IV
PROVIDER: S-EPMC4384823 | biostudies-literature | 2014 Oct
REPOSITORIES: biostudies-literature
Fedorenko Inna V IV Fang Bin B Koomen John M JM Gibney Geoffrey T GT Smalley Keiran S M KS Smalley Keiran S M KS
Melanoma research 20141001 5
Effective targeted therapy strategies are still lacking for the 15-20% of melanoma patients whose melanomas are driven by oncogenic NRAS. Here, we report on the NRAS-specific behavior of amuvatinib, a kinase inhibitor with activity against c-KIT, Axl, PDGFRα, and Rad51. An analysis of BRAF-mutant and NRAS-mutant melanoma cell lines showed the NRAS-mutant cohort to be enriched for targets of amuvatinib, including Axl, c-KIT, and the Axl ligand Gas6. Increasing concentrations of amuvatinib selecti ...[more]